Loading organizations...
Key people at Maximon.
Maximon functions as a company builder and accelerator within the longevity sector. It develops and scales science-based enterprises offering healthy aging and rejuvenation solutions. Their portfolio encompasses evidence-backed supplements, genetic improvements, and personalized health interventions, empowering entrepreneurs to advance human healthspan in this value chain. The firm systematically identifies and supports ventures focused on extending a healthy human life.
Founded in 2021 by Dr. Tobias Reichmuth, Marc P. Bernegger, Jörg Rieker, and Caroline Wagner, Maximon emerged from the insight that an opportunity existed to build scalable businesses addressing human healthspan extension. This understanding led to their venture studio model, which systematically fosters innovation in the burgeoning field of longevity science. The founders leverage their collective expertise to cultivate new companies directly.
Maximon's portfolio companies serve individuals seeking enhanced health and well-being as they age. Its long-term vision positions it as a pivotal force in the global longevity economy, aiming to shape human healthspan’s future by identifying, incubating, and expanding enterprises that contribute to a longer, healthier life. The company remains forward-looking in its pursuit of advanced health solutions.
Key people at Maximon.
Maximon has 10 tracked investments across 6 companies. The latest tracked deal is $4.0M Series A in rready in November 2023.
Maximon is a Swiss-based company builder and investment firm focused on creating and scaling science-based ventures that provide healthy aging and rejuvenation solutions within the longevity industry. It empowers entrepreneurs by offering a structured venture-building process that bridges scientific research and business execution, targeting startups with measurable, science-backed impacts on human aging. Maximon’s portfolio spans a broad longevity value chain, including evidence-based supplements, personalized health analytics, co-living solutions for active seniors, and healthspan clinics, all aimed at extending healthspan and improving quality of life today. Their ventures demonstrate strong growth momentum, with some, like Avea Life, achieving profitability and rapid revenue growth within a few years of launch[1][2][4].
Founded in 2021 and headquartered in Zurich, Maximon was established by a team of globally experienced entrepreneurs and venture investors led by founding partner Marc P Bernegger. The firm’s origin lies in identifying promising business models in longevity that have existing markets and short-term revenue potential, differentiating itself from longer-term biotech-focused longevity investors. Maximon employs a rigorous validation phase lasting six to nine months involving market analysis and customer research before company creation and financing. Since inception, it has launched five longevity companies and maintains a robust pipeline of new ventures exploring areas such as the microbiome, skin longevity, animal longevity, and cancer prevention[2][3].
Maximon rides the growing global trend of longevity and healthy aging, a sector gaining momentum due to demographic shifts, rising healthcare costs, and increasing consumer interest in life extension and quality of life improvements. The firm’s timing is strategic, capitalizing on advances in science and technology that enable scalable, evidence-based healthspan solutions. By building companies that address immediate market needs, Maximon influences the broader ecosystem by demonstrating that longevity ventures can be both impactful and financially viable in the near term. This approach helps attract more investment and innovation into the longevity space, fostering a more vibrant startup ecosystem focused on aging-related challenges[1][2][4].
Maximon is poised to expand its influence in the longevity industry by continuing to launch and scale ventures that deliver measurable healthspan improvements. With a growing pipeline of projects in emerging longevity subfields like the microbiome and cancer prevention, the firm is well-positioned to capitalize on evolving scientific breakthroughs and consumer trends. As global populations age, demand for innovative, science-backed longevity solutions will likely increase, enhancing Maximon’s role as a key enabler of healthy aging startups. Their model of combining rigorous validation with rapid commercialization may set a new standard for longevity venture building, potentially accelerating the sector’s growth and impact in the coming years[2][4].
